StreetInsider.com News Articles

Form 4 Quanterix Corp For: Jul 15 Filed by: Miller Michael Francis

Thu, 16 Jul 2026 17:33:00 -0400

si-local-file:///var/storage/secattach/20260716/26780731.html

Form 4 Quanterix Corp For: Jul 15 Filed by: Miller Michael Francis

Thu, 16 Jul 2026 17:33:00 -0400

si-local-file:///var/storage/secattach/20260716/26780731.html

Form 4 Quanterix Corp For: Jul 15 Filed by: Faessler Jason F.

Thu, 16 Jul 2026 17:32:00 -0400

si-local-file:///var/storage/secattach/20260716/26780721.html

Form 4 Quanterix Corp For: Jul 15 Filed by: Faessler Jason F.

Thu, 16 Jul 2026 17:32:00 -0400

si-local-file:///var/storage/secattach/20260716/26780721.html

Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Thu, 16 Jul 2026 16:05:00 -0400

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that on July 15, 2026, an inducement grant (the “Inducement Grant”) was made to Jason Faessler in connection with the commencement of his employment as the Chief Financial officer and Treasurer of the Company. The Inducement Grant consisted of 141,820 restricted stock units (“RSUs”) representing 141,820 shares of Quanterix common stock.

The RSUs vest in four equal annual installments on the first four anniversaries of the grant date, subject to Mr. Faessler’s continued employment with the Company or

Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Thu, 16 Jul 2026 16:05:00 -0400

The RSUs vest in four equal annual installments on the first four anniversaries of the grant date, subject to Mr. Faessler’s continued employment with the Company or

Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Thu, 16 Jul 2026 16:05:00 -0400

The RSUs vest in four equal annual installments on the first four anniversaries of the grant date, subject to Mr. Faessler’s continued employment with the Company or

Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Thu, 16 Jul 2026 16:05:00 -0400

The RSUs vest in four equal annual installments on the first four anniversaries of the grant date, subject to Mr. Faessler’s continued employment with the Company or

Anthem to cover Quanterix Alzheimer's blood test starting July 2026

Tue, 14 Jul 2026 16:29:18 -0400

Quanterix Corporation (NASDAQ: QTRX) announced that Anthem Blue Cross and Blue Shield will begin covering blood-based biomarker testing for Alzheimer's disease under its medical policies starting July 1, 2026, when medical necessity criteria are met.

Anthem, which provides medical coverage to approximately 40 million members across 14 states, states it is the first commercial insurer in the United States to establish such a policy. The coverage includes Quanterix's LucentAD® Complete, a five-analyte blood test that measures biomarkers associated with amyloid pathology, tau pathology, neurodegeneration, and neuroinflammation.

Quanterix also announced publication of a peer-reviewed study in Alzheimer's & Dementia: Diagnosis, Assessment & Disease

Anthem to cover Quanterix Alzheimer's blood test starting July 2026

Tue, 14 Jul 2026 16:29:18 -0400

Quanterix Corporation (NASDAQ: QTRX) announced that Anthem Blue Cross and Blue Shield will begin covering blood-based biomarker testing for Alzheimer's disease under its medical policies starting July 1, 2026, when medical necessity criteria are met.

Anthem, which provides medical coverage to approximately 40 million members across 14 states, states it is the first commercial insurer in the United States to establish such a policy. The coverage includes Quanterix's LucentAD® Complete, a five-analyte blood test that measures biomarkers associated with amyloid pathology, tau pathology, neurodegeneration, and neuroinflammation.

Quanterix also announced publication of a peer-reviewed study in Alzheimer's & Dementia: Diagnosis, Assessment & Disease

Anthem to cover Quanterix Alzheimer's blood test starting July 2026

Tue, 14 Jul 2026 16:29:18 -0400

Quanterix Corporation (NASDAQ: QTRX) announced that Anthem Blue Cross and Blue Shield will begin covering blood-based biomarker testing for Alzheimer's disease under its medical policies starting July 1, 2026, when medical necessity criteria are met.

Anthem, which provides medical coverage to approximately 40 million members across 14 states, states it is the first commercial insurer in the United States to establish such a policy. The coverage includes Quanterix's LucentAD® Complete, a five-analyte blood test that measures biomarkers associated with amyloid pathology, tau pathology, neurodegeneration, and neuroinflammation.

Quanterix also announced publication of a peer-reviewed study in Alzheimer's & Dementia: Diagnosis, Assessment & Disease

Anthem to cover Quanterix Alzheimer's blood test starting July 2026

Tue, 14 Jul 2026 16:29:18 -0400

Quanterix Corporation (NASDAQ: QTRX) announced that Anthem Blue Cross and Blue Shield will begin covering blood-based biomarker testing for Alzheimer's disease under its medical policies starting July 1, 2026, when medical necessity criteria are met.

Anthem, which provides medical coverage to approximately 40 million members across 14 states, states it is the first commercial insurer in the United States to establish such a policy. The coverage includes Quanterix's LucentAD® Complete, a five-analyte blood test that measures biomarkers associated with amyloid pathology, tau pathology, neurodegeneration, and neuroinflammation.

Quanterix also announced publication of a peer-reviewed study in Alzheimer's & Dementia: Diagnosis, Assessment & Disease

Anthem to cover Quanterix Alzheimer's blood test starting July 2026

Tue, 14 Jul 2026 16:29:18 -0400

Quanterix Corporation (NASDAQ: QTRX) announced that Anthem Blue Cross and Blue Shield will begin covering blood-based biomarker testing for Alzheimer's disease under its medical policies starting July 1, 2026, when medical necessity criteria are met.

Anthem, which provides medical coverage to approximately 40 million members across 14 states, states it is the first commercial insurer in the United States to establish such a policy. The coverage includes Quanterix's LucentAD® Complete, a five-analyte blood test that measures biomarkers associated with amyloid pathology, tau pathology, neurodegeneration, and neuroinflammation.

Quanterix also announced publication of a peer-reviewed study in Alzheimer's & Dementia: Diagnosis, Assessment & Disease

Anthem to cover Quanterix Alzheimer's blood test starting July 2026

Tue, 14 Jul 2026 16:29:18 -0400

Quanterix Corporation (NASDAQ: QTRX) announced that Anthem Blue Cross and Blue Shield will begin covering blood-based biomarker testing for Alzheimer's disease under its medical policies starting July 1, 2026, when medical necessity criteria are met.

Anthem, which provides medical coverage to approximately 40 million members across 14 states, states it is the first commercial insurer in the United States to establish such a policy. The coverage includes Quanterix's LucentAD® Complete, a five-analyte blood test that measures biomarkers associated with amyloid pathology, tau pathology, neurodegeneration, and neuroinflammation.

Quanterix also announced publication of a peer-reviewed study in Alzheimer's & Dementia: Diagnosis, Assessment & Disease

Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

Tue, 14 Jul 2026 16:29:00 -0400

Beginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies support eligible blood-based biomarker testing
New peer-reviewed and AAIC data reinforce the clinical value of Quanterix's LucentAD® Complete multi-biomarker blood

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer’s testing. Together, these milestones reinforce the growing role of LucentAD® Complete, Quanterix’s five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate Alzheimer’s disease through a comprehensive, blood-based assessment.
The announcements include:

Anthem Blue Cross and Blue Shield eligible members

Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

Tue, 14 Jul 2026 16:29:00 -0400

Beginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies support eligible blood-based biomarker testing
New peer-reviewed and AAIC data reinforce the clinical value of Quanterix's LucentAD® Complete multi-biomarker blood

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer’s testing. Together, these milestones reinforce the growing role of LucentAD® Complete, Quanterix’s five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate Alzheimer’s disease through a comprehensive, blood-based assessment.
The announcements include:

Anthem Blue Cross and Blue Shield eligible members

Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

Tue, 14 Jul 2026 16:29:00 -0400

Beginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies support eligible blood-based biomarker testing
New peer-reviewed and AAIC data reinforce the clinical value of Quanterix's LucentAD® Complete multi-biomarker blood

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer’s testing. Together, these milestones reinforce the growing role of LucentAD® Complete, Quanterix’s five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate Alzheimer’s disease through a comprehensive, blood-based assessment.
The announcements include:

Anthem Blue Cross and Blue Shield eligible members

Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

Tue, 14 Jul 2026 16:29:00 -0400

Beginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies support eligible blood-based biomarker testing
New peer-reviewed and AAIC data reinforce the clinical value of Quanterix's LucentAD® Complete multi-biomarker blood

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer’s testing. Together, these milestones reinforce the growing role of LucentAD® Complete, Quanterix’s five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate Alzheimer’s disease through a comprehensive, blood-based assessment.
The announcements include:

Anthem Blue Cross and Blue Shield eligible members

Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

Tue, 14 Jul 2026 16:29:00 -0400

Beginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies support eligible blood-based biomarker testing
New peer-reviewed and AAIC data reinforce the clinical value of Quanterix's LucentAD® Complete multi-biomarker blood

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer’s testing. Together, these milestones reinforce the growing role of LucentAD® Complete, Quanterix’s five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate Alzheimer’s disease through a comprehensive, blood-based assessment.
The announcements include:

Anthem Blue Cross and Blue Shield eligible members

Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

Tue, 14 Jul 2026 16:29:00 -0400

Beginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies support eligible blood-based biomarker testing
New peer-reviewed and AAIC data reinforce the clinical value of Quanterix's LucentAD® Complete multi-biomarker blood

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer’s testing. Together, these milestones reinforce the growing role of LucentAD® Complete, Quanterix’s five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate Alzheimer’s disease through a comprehensive, blood-based assessment.
The announcements include:

Anthem Blue Cross and Blue Shield eligible members

Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

Tue, 14 Jul 2026 16:29:00 -0400

Beginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies support eligible blood-based biomarker testing
New peer-reviewed and AAIC data reinforce the clinical value of Quanterix's LucentAD® Complete multi-biomarker blood

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer’s testing. Together, these milestones reinforce the growing role of LucentAD® Complete, Quanterix’s five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate Alzheimer’s disease through a comprehensive, blood-based assessment.
The announcements include:

Anthem Blue Cross and Blue Shield eligible members

Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

Tue, 14 Jul 2026 16:29:00 -0400

Beginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies support eligible blood-based biomarker testing
New peer-reviewed and AAIC data reinforce the clinical value of Quanterix's LucentAD® Complete multi-biomarker blood

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer’s testing. Together, these milestones reinforce the growing role of LucentAD® Complete, Quanterix’s five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate Alzheimer’s disease through a comprehensive, blood-based assessment.
The announcements include:

Anthem Blue Cross and Blue Shield eligible members

Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

Tue, 14 Jul 2026 16:29:00 -0400

Beginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies support eligible blood-based biomarker testing
New peer-reviewed and AAIC data reinforce the clinical value of Quanterix's LucentAD® Complete multi-biomarker blood

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer’s testing. Together, these milestones reinforce the growing role of LucentAD® Complete, Quanterix’s five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate Alzheimer’s disease through a comprehensive, blood-based assessment.
The announcements include:

Anthem Blue Cross and Blue Shield eligible members

Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

Tue, 14 Jul 2026 16:29:00 -0400

Beginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies support eligible blood-based biomarker testing
New peer-reviewed and AAIC data reinforce the clinical value of Quanterix's LucentAD® Complete multi-biomarker blood

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer’s testing. Together, these milestones reinforce the growing role of LucentAD® Complete, Quanterix’s five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate Alzheimer’s disease through a comprehensive, blood-based assessment.
The announcements include:

Anthem Blue Cross and Blue Shield eligible members

Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

Tue, 14 Jul 2026 16:29:00 -0400

Beginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies support eligible blood-based biomarker testing
New peer-reviewed and AAIC data reinforce the clinical value of Quanterix's LucentAD® Complete multi-biomarker blood

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer’s testing. Together, these milestones reinforce the growing role of LucentAD® Complete, Quanterix’s five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate Alzheimer’s disease through a comprehensive, blood-based assessment.
The announcements include:

Anthem Blue Cross and Blue Shield eligible members